Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Breast Cancer Symposium

Excerpt from the Press Release:

DUBLIN, Ireland and BOSTON, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today at the 2021 San Antonio Breast Cancer Symposium (SABCS), presented encouraging clinical data on samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, that support its continued development in breast cancer.

Carrick presented updated data from a Phase 1b/2 clinical trial for samuraciclib in combination with fulvestrant in women with hormone receptor positive (HR+), HER2- advanced breast cancer (BC) previously treated with a CDK4/6 inhibitor (abstract: GS3-10) that reinforces encouraging clinical activity and tolerability and supports further development of the combination.

“The data we announced at SABCS both demonstrated clinical activity and tolerability, which has reinforced our conviction that samuraciclib has potential to be a first and best-in-class treatment,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics. “Our pre-clinical studies have established that CDK7 inhibition activates the p53 pathway in TP53 wild-type, HR+ breast cancer cells. More importantly, p53 pathway activation by samuraciclib in combination with CDK7 inhibition has been effective in controlling cancer growth in our HR+ clinical study. Samuraciclib, provides meaningful benefit most notably in those women that are TP53 wildtype, which accounts for nearly 70% of patients in this setting. Samuraciclib in combination with fulvestrant in the post CDK4/6 setting has demonstrated a median mPFS of 32 weeks. This is a meaningful prolongation of PFS considering the limited benefit these patients have with endocrine monotherapy therapy, which is limited to only ~8 weeks mPFS with fulvestrant alone in previously reported studies. Having now validated the biology for SERD combination, we continue to explore additional options, including our collaboration with Roche’s giredestrant, a next-generation oral SERD. We believe there is potential for synergy in combining samuraciclib with oral SERDs to significantly enhance the benefits already demonstrated with fulvestrant . We are excited with the progress we’ve made, and we look forward to additional data readouts from our ongoing programs.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release